London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Looking forward to an interesting week here. Some good research chaps
The BD FocalPoint™ is the ONLY automated technology for cervical cancer screening approved for use by the NHS . Thats 2 contracts off a potential 170 NHS Trusts in england alone AND discussions current for further contracts. Bearing in mind its the only approved technology its reasonable to be very optimistic about securing further contracts. We also have to bear in mind SBS has a diversified business model targeting Healthcare, Lifesciences & Pharmabiotech of which the company are european leaders in integral aspects of the lifesciences business. Established robust revenue streams and an expanding market make this a very solid company to invest in in with strong newsflow expectations in the coming months imo
The commitment to the BD FocalPoint™ system by a second NHS Trust Does that mean only one committed at the time of Dr. Ash' comment?
Theres about 170 Acute Trusts in England which make the decisions regarding the implementation of the new cervical cancer screening technology ( BD FocalPoint) offered by SBS. The BD FocalPoint™ is the ONLY automated technology for cervical cancer screening approved for use by the NHS . There currently talking to other Trusts which are expected to yield further contracts towards making this the standard diagnostic method across all the NHS trusts in England & Wales. Shaping up well for some very strong newsflow on contract acquisitions. Thats why we had the director buys recently and the purchase of the head office with major growth expectations in the short,medium & long term throughout all divisions. An exceptional biotech investment imho but dyor http://www.sourcebioscience.com/ http://www.moneyam.com/action/news/showArticle?id=4258170 http://www.moneyam.com/action/news/showArticle?id=4301051
Good to see you here too. Value your input and open to anyone else regarding those possible negatives to the investment case. Atb
A good rise today and probably the start of further increases as pi's become aware of the strength of fundamentals here. Unlike a lot of companies in the biotech sector its not heavily debt laden and already has a strong revenue stream from a diversified product base. Its the european market leader in at least one of those with all target sectors growing. Its no wonder weve had recent large director buys and the lilelihood of further newsflow in the near term. As Nick Ash (CEO) said in the 1st Feb RNS "Since publication of the implementation guidelines by the NHS, there has been considerable interest from many NHS Trusts in adopting the technology. The commitment to the BD FocalPoint™ system by a second NHS Trust demonstrates the confidence there is in this technology and we're delighted that Pennine Acute NHS Hospitals Trust has added the BD FocalPoint™ to its screening programme. There are a number of ongoing discussions with other NHS Trusts and we expect further announcements in the months ahead." I found it very difficult to buy today at the ask price. With strong fundamentals, revenue stream & newsflow expectations this has tremendous growth potential written all over it and is only now beginning to attract wider investor interest. Any negative points to the investment case are welcome as cant see much against the stock. A very good prospect especially within the sector imho Dyor & gla
4 October 2011 Source BioScience plc ("Source BioScience" or the "Company") Source BioScience launches world's fastest combined DNA sequencing and data analysis service in Germany New Overnight Service to target researchers in Berlin Source BioScience (LSE: SBS), the international diagnostics and genetic analysis business, has extended the reach of its DNA sequencing and data analysis service in Europe with the launch of its Overnight Service in Germany, effective from 4 October 2011. The Overnight Service for DNA sequencing will now be available to research teams in and around Berlin, with customers receiving their sequencing results by 9am the next day, including Saturdays, at no extra cost. The DNA sequencing and data analysis service has been operational since June, when it was launched in the UK, and it targets the Life Sciences Research sector with the offer of free sample collection and super fast delivery of results. It combines Source BioScience's world class sequencing capabilities with its unique SpeedREAD™ automated data delivery system. Dr Nick Ash, CEO at Source BioScience, commented: "We believe our Overnight Service sets a new standard in sequencing services and that it can play a major part in reducing downtime in research projects by delivering results in a timely fashion. We are delighted to extend the service to our German customers." He added, "The Overnight Service is also having a very positive impact on our business, with a significant increase in sequencing volumes since its launch in June 2011. We look forward to seeing this service being taken up by other research teams throughout Europe in due course."
Looks like they could be short on stock... Very tough to buy here with a sizeable amount. Sometimes you could only buy 2500 a go... but when it goes to NT is ready to tick up.
i will take a look over the weekend at that one. cheers pal
at 8.5p though damn you pablo lol
Finally got in and got 10,850 @ 8.25p They kept offering me 9p automatically but SimplyStockbroking rang mm and got 8.25p
would you buy if you could get a 9p quote lol
spread is higher than 3% i was offered 9p too!!!!
No problem,thinking this has been an excellent week for you,and hats off,well done impho-GL Have a great weekend yourself!
You can deal with me if you like??!?! 15p for my lot? lol
2x 500k on my app showing as negotiated trades. So buying by possibly the same ii as yesterday?
9p!
Presumably sells?
I read the article earlier and a good read. I am in with a few bob. Looks like the market missed this one... Although they have some big hitters on the shareholders! ; )
Looks good to me. They have slowly been getting on with the business. Very difficult to buy a decent size here. Can you see any broker notes on this one for a target price?